Skip to main content

Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

Risk for Pediatric Firearm Reinjury 6 Percent at One Year After Initial Injury

MONDAY, Sept. 16, 2024 -- The risk for firearm reinjury among children who present with acute nonfatal firearm injury is 6 and 14 percent at one and five...

Childhood BMI Linked to Increased Risk for Schizophrenia

MONDAY, Sept. 16, 2024 -- Childhood body mass index (BMI) has a direct and enduring effect on the risk for schizophrenia later in life, according to a study...

Gestational Hypertension Tied to Higher Later Risk for Cardiovascular Disease

MONDAY, Sept. 16, 2024 -- A self-reported history of gestational hypertension is associated with cardiovascular disease (CVD) in postmenopausal women...

FDA Approves Tremfya for Ulcerative Colitis

MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely...

Most Tobacco Instagram Posts Do Not Adhere to FDA Warning Requirements

MONDAY, Sept. 16, 2024 -- Most nicotine brand Instagram posts do not adhere to U.S. Food and Drug Administration (FDA) health warning requirements for tobacco...

Ozempic Could Curb Progression of Diabetes-Linked Liver Disease

MONDAY, Sept. 16, 2024 -- Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP-1...

Breathing Could Bring Microplastics Into the Human Brain, Study Shows

MONDAY, Sept. 16, 2024 -- For the first time, scientists have detected microscopic microplastics lodged in the human brain. Researchers in Germany and Brazil...

Pregnancy Changes the Brain, Study Finds

MONDAY, Sept. 16, 2024 -- With implications for research around postpartum depression and other health issues, scientists have tracked the changes pregnancy...

Genetics Suggest Link Between ALS, Parkinson's Disease

MONDAY, Sept. 16, 2024 -- People with rare genetic variants linked to degenerative brain disorders like Parkinson’s disease are at increased risk of...

Missouri Bird Flu Case Raises Possibility of Human Transmission

MONDAY, Sept. 16, 2024 (Healthday News) -- In a disclosure that can't eliminate the possibility that bird flu may have spread from one human to another for the...

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

FDA Approves Lilly's Ebglyss (lebrikizumab) for Atopic Dermatitis

Ebglyss provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with...

FDA Approves Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

South San Francisco, CA -- September 12, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and...

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has...

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S. Food...

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies...

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Spring House, Pa. (August 29, 2024) – Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and...

Emergent BioSolutions’ ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA)...

Telix Submits NDA for TLX101-CDx (Pixclara) Brain Cancer Imaging Agent

MELBOURNE, Australia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New...

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on...

Trishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer Patients

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2024. Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today reported final results...

Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington's Disease

LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases...

Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

SAN DIEGO, Sept. 12, 2024. Neurocrine Biosciences, Inc. today announced that its ERUDITE Phase 2 clinical study of investigational compound luvadaxistat...

Biolexis Unveils Promising Data with an Oral Weight Loss Drug: BLX-7006 Shows Significant Results in Preclinical Studies

LEHI, Utah., Sept. 12, 2024. Biolexis Therapeutics, a biopharmaceutical company pioneering next-generation weight loss treatments, today announced the...

Dupixent Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria

TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Dupixent (dupilumab) confirmatory Phase 3 trial...

Browse by news type

Drugs.com Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Disclaimer

This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.